Johnson TA and Singla DK |
Breast cancer drug trastuzumab induces cardiac toxicity: evaluation of human epidermal growth factor receptor 2 as a potential diagnostic and prognostic marker. |
2018 |
Can. J. Physiol. Pharmacol. |
pmid:29842793
|
Welslau M et al. |
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. |
2014 |
Cancer |
pmid:24222194
|
Moore KN et al. |
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. |
2017 |
Cancer |
pmid:28440955
|
Franklin R et al. |
A phase I-II study of maytansine utilizing a weekly schedule. |
1980 |
Cancer |
pmid:7214295
|
Beeram M et al. |
A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. |
2012 |
Cancer |
pmid:22648179
|
Osieka R et al. |
Chemotherapy of human colon cancer xenografts in athymic nude mice. |
1977 |
Cancer |
pmid:144557
|
Li JY et al. |
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. |
2016 |
Cancer Cell |
pmid:26766593
|
Chen SC et al. |
Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). |
2017 |
Cancer Chemother. Pharmacol. |
pmid:29043411
|
Li C et al. |
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane. |
2017 |
Cancer Chemother. Pharmacol. |
pmid:29022084
|
Douros J and Suffness M |
New natural products of interest under development at the National Cancer Institute. |
1978 |
Cancer Chemother. Pharmacol. |
pmid:86390
|
Lu D et al. |
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. |
2014 |
Cancer Chemother. Pharmacol. |
pmid:24939213
|
Li C et al. |
Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer. |
2016 |
Cancer Chemother. Pharmacol. |
pmid:27423671
|
Wada R et al. |
Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates. |
2014 |
Cancer Chemother. Pharmacol. |
pmid:25186956
|
Rodon J et al. |
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. |
2008 |
Cancer Chemother. Pharmacol. |
pmid:18301896
|
Girish S et al. |
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. |
2012 |
Cancer Chemother. Pharmacol. |
pmid:22271209
|
Bender BC et al. |
A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. |
2012 |
Cancer Chemother. Pharmacol. |
pmid:22886072
|
Carter SK |
New drugs under clinical evaluation in the United States. |
1978 |
Cancer Chemother. Pharmacol. |
pmid:155503
|
Blum RH et al. |
A therapeutic trial of maytansine. |
1978 |
Cancer Clin Trials |
pmid:757139
|
|
T-DM1 aids patients with advanced breast cancer. |
2013 |
Cancer Discov |
pmid:24327714
|
|
T-DM1 Combo Graduates from I-SPY 2. |
2016 |
Cancer Discov |
pmid:27095360
|